Create an Account

Wrinkle remover Revance files for $86 million IPO

01/06/2014

Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We’re glad to see you’re enjoying PracticalDermatology…
    but how about a more personalized experience?

    Register for free
    You are now leaving PracticalDermatology and going to a site run by another organization.

    Press cancel to remain on PracticalDermatology. Press the link below or the continue button to keep going.